文献速递艾滋病与性传播感染病毒性肝炎

HIV合并HCV感染者DAA治疗后肝细胞癌风险

Risk of Hepatocellular Carcinoma After Direct-Acting Antiviral Treatment for Hepatitis C Virus Infection in People With HIV.
PubMed 文献 · Clin Infect Dis · 2026-01-01

基于HepCAUSAL多队列协作,纳入3824例HIV-HCV共感染且晚期肝纤维化或肝硬化、DAA初治者,采用加权合并logistic模型估计全员启动DAA情形下6年HCC风险。估计6年HCC风险为2.5%(95%CI 1.6–3.9),年HCC概率由第1年0.81%逐步降至第5–6年0.10%。

要点

  • HIV-HCV共感染伴晚期肝纤维化或肝硬化者DAA后6年HCC风险约2.5%
  • 年HCC概率随时间下降,3年后降至0.4%以下
  • 提示可据此调整DAA治愈后HCC监测策略

核心结论

  • HIV合并HCV感染且存在晚期肝纤维化或肝硬化者,DAA治疗后6年内估计2.5%被诊断HCC,年概率随时间下降并于3年后低于0.4%。

研究设计与样本

  • 采用HepCAUSAL协作的欧洲与北美HIV-HCV共感染队列数据,纳入3824例符合条件者,其中2373例(62%)启动DAA。
  • 以加权合并logistic模型估计全员基线启动DAA情形下的6年HCC风险与年度HCC概率,随访至HCC诊断、死亡、失访、6年或数据库关闭。

主要发现

  • 随访期间43例被诊断HCC。
  • 全体启动DAA情形下估计6年HCC风险为2.5%(95%CI 1.6–3.9)。
  • 年HCC概率:基线至第12个月0.81%(95%CI 0.34–1.54),1–2年0.64%(0.28–1.19),2–3年0.50%(0.27–0.84),3–4年0.34%(0.13–0.63),4–5年0.19%(0.07–0.33),5–6年0.10%(0.01–0.24)。

关键数值与推荐

  • 纳入标准为HIV-HCV共感染、晚期肝纤维化或肝硬化、DAA初治、HIV-RNA<50 copies/mL、正在接受抗逆转录病毒治疗、无HBV共感染、无既往HCC诊断或肝移植。
  • 纳入人群92%为男性,中位年龄60岁(IQR 54–64)。

临床怎么用

  • 结果可用于指导HIV合并HCV感染且晚期肝纤维化或肝硬化者DAA治愈后HCC监测的强度与持续时间安排。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To inform hepatocellular carcinoma (HCC) surveillance after hepatitis C virus (HCV) cure with direct-acting antivirals (DAA), we estimated HCC risk post-DAA in people with human immunodeficiency virus (HIV) with advanced liver fibrosis or cirrhosis under universal DAA. METHODS: We used data from HepCAUSAL, a collaboration of cohorts of HIV-HCV coinfection from Europe and North America. Eligibility criteria were HIV-HCV coinfection, advanced liver fibrosis or cirrhosis, DAA naïve, HIV-RNA < 50 copies/mL, on antiretroviral therapy, no HBV coinfection, and no prior HCC diagnosis or liver transplant. Follow-up started when eligibility was met and ended at HCC diagnosis, death, loss to follow-up, 6 years, or database closure, whichever came first. We estimated the 6-year risk and annual probability of HCC if all eligible individuals had initiated DAA at baseline using a weighted pooled logistic model for the monthly HCC risk among DAA initiators. RESULTS: Of 3824 eligible individuals (92% males, median age 60 years [IQR: 54, 64]), 2373 (62%) who initiated DAA, 43 had an HCC diagnosis during follow-up. The estimated 6-year HCC risk (95% CI) under universal DAA was 2.5% (1.6, 3.9). Annual HCC probability was 0.81% (0.34, 1.54) between baseline and month 12 after DAA initiation, 0.64% (0.28, 1.19) between years 1 and 2, 0.50% (0.27, 0.84) between years 2 and 3, 0.34% (0.13, 0.63) between years 3 and 4, 0.19% (0.07, 0.33) between years 4 and 5, and 0.10% (0.01, 0.24) between years 5 and 6. CONCLUSIONS: An estimated 2.5% of people with HIV and advanced liver fibrosis or cirrhosis are diagnosed with HCC by 6 years post-DAA. Annual probability of HCC declines over time and falls below 0.4% after 3 years.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. van Santen DK, Chalouni M, Berenguer J, et al. Risk of Hepatocellular Carcinoma After Direct-Acting Antiviral Treatment for Hepatitis C Virus Infection in People With HIV. Clin Infect Dis. 2026. PMID: 41253696. doi:10.1093/cid/ciaf635

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。